Myelofibrosis Highlights From EHA 2024

Published Date: 09 Jul 2024

Highlights in myelofibrosis from EHA 2024 include results of pelabresib-ruxolitinib combination therapy, final analysis of jaktinib compared to hydroxyurea, and safety and efficacy of elritercept.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot